Stada Bows To Activist AOC, Opens Bidding Process To Three Suitors
Executive Summary
Stada's supervisory board says it will play cards the way Active Ownership Capital wants for the time being, and has now opened the M&A game centered on the German group to a "structured bidding process".
You may also be interested in...
Cinven's M&A Ambitions Over Stada Under Scrutiny, Advent and Others Circle
By stalking Stada, Cinven seems to be planning to use the German generics group as a base that can support later carve-outs of mature and undervalued products from larger pharma companies - but it faces a rival bidder in Advent, and more suitors could yet appear.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.